Horizon Therapeutics Announces Dealing Disclosure by Director

Horizon Therapeutics plc, a leading biopharmaceutical company, has disclosed a dealing made by one of its directors, Gino Santini. The disclosure was made in accordance with Rule 8.1(c) and (d)(i) of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Gino Santini, who is acting in concert with Horizon Therapeutics as a director, revealed that he owns and/or controls 195,492 ordinary shares of the company, representing 0.085% of the total outstanding shares. The disclosure was made on October 2, 2023.

The disclosure form also states that there were no purchases, sales, cash-settled derivative transactions, or stock-settled derivative transactions made by Gino Santini in relation to Horizon Therapeutics’ securities.

Horizon Therapeutics is a global biopharmaceutical company focused on researching, developing, and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. The company is committed to improving the lives of patients and providing them with access to life-changing therapies.

This dealing disclosure by Gino Santini highlights the transparency and adherence to regulatory requirements demonstrated by Horizon Therapeutics. The company remains dedicated to maintaining strong corporate governance practices and ensuring the fair and ethical treatment of its shareholders.

For more information about Horizon Therapeutics and its ongoing developments, please visit their official website.